[Secondary prevention after deep venous thrombosis. Low molecular weight heparin versus coumarin].
In numerous clinical trials low molecular weight heparins (LMWHs) have proven to be highly efficacious and safe in preventing thromboembolic complications. There is also a strong evidence that for the prevention of recurrence after deep venous thrombosis LMWHs lead to results comparable to those of dose-adjusted coumarin: in a monocentric randomized prospective study 200 patients after conservatively or surgically treated deep vein thrombosis received either a fixed dose of LMWH (5000 U anti-Xa; Fragmin P forte) s.c. or dose-adjusted coumarin (Marcumar) p.o. during a period of 3-6 months. During a follow-up of 12 months there was no significant difference between both groups regarding recurrence of deep vein thrombosis but three major bleeding complications in the coumarin-group (none in the LMWH-group) occurred.
Hamann
H
H
Gefässchirurgische Abteilung, Kreiskrankenhaus Leonberg.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D010644:Phenprocoumon / Q000008:administration & dosage* / Q000009:adverse effects; D011183:Postoperative Complications / Q000517:prevention & control*; D019106:Postoperative Hemorrhage / Q000139:chemically induced; D011446:Prospective Studies; D012008:Recurrence; D012307:Risk Factors; D013924:Thrombophlebitis / Q000517:prevention & control*; D016896:Treatment Outcome
D006495:Heparin, Low-Molecular-Weight; D010644:Phenprocoumon